Related Experiment Video

Updated: May 22, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Safety of 5% Topical 5-Fluorouracil in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Multicenter

Goranit Sakunchotpanit1,2, Farrah L Ezzeddine1,3, Gerry Serwald1,3

  • 1Brigham and Women's Hospital, Department of Dermatology, Boston, MA, USA.

The British Journal of Dermatology
|May 20, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Related Experiment Videos

Last Updated: May 22, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Articles linked to this work by shared authors, journal, and citation graph.

AI Simplification of Dermatopathology Reports for Patients: Basic Versus Prompt-Engineered Approaches.

Journal of cutaneous pathology·2026

Primary Cutaneous Anaplastic Large Cell Lymphoma in a Patient With Li Fraumeni Syndrome.

The American Journal of dermatopathology·2026

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome: An emerging autoinflammatory paraneoplastic disorder.

Clinics in dermatology·2026

High-Dose Oral Vitamin D for Toxic Effects of the Skin Associated With Chemotherapy and Radiation.

JAMA dermatology·2026

Mpox Outbreaks Beyond Historically Endemic Regions: A Clinical Review of Vaccination Strategies and Public Health Challenges.

Dermatology (Basel, Switzerland)·2026

Patchy presentation of central centrifugal cicatricial alopecia.

Dermatology online journal·2026

Precision Medicine for Somatic Mutation-Driven Vascular Anomalies.

The British journal of dermatology·2026

Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data.

The British journal of dermatology·2026

Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial.

The British journal of dermatology·2026

Five-year Recurrence Rate of Cutaneous Squamous Cell Carcinoma After Mohs Micrographic Surgery Versus Standard Excision: a Prospective Multicentre Cohort Study.

The British journal of dermatology·2026

CD1a-autoreactive T cell sensing of skin barrier compromise.

The British journal of dermatology·2026

Co-occurrence of GATA2 deficiency and probable constitutional mosaic STAG2 alteration in a young adult with myelodysplastic syndrome: a case report.

Frontiers in medicine·2026

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Haematologica·2026

Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.

Current vascular pharmacology·2026

Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort.

The American journal of surgical pathology·2026

TH/TRs-COL11A2 Axis Mediates Loss of a Differentiated Astrocyte State in Hypogyrified Brains.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.

Virus genes·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us